DOCS vs LLY

For growth investors, Eli Lilly and Company (LLY) is the stronger pick with 44.

7% revenue growth year-over-year, versus 13. 1% for Doximity, Inc. (DOCS). Doximity, Inc. (DOCS) offers the better valuation at 20. 4x trailing P/E (14. 0x forward), making it the more compelling value choice. Analysts rate Eli Lilly and Company (LLY) a "Buy" — based on 45 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Doximity, Inc.

(DOCS) is the cheapest at 20. 4x versus Eli Lilly and Company at 49. 4x. On forward P/E, Doximity, Inc. is actually cheaper at 14. 0x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Doximity, Inc. wins at 0. 27x versus Eli Lilly and Company's 1. 07x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

Over the past 5 years, Eli Lilly and Company (LLY) delivered a total return of +412.

1%, compared to -62. 2% for Doximity, Inc. (DOCS). Over 10 years, the gap is even starker: LLY returned +1485% versus DOCS's -62. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Eli Lilly and Company (LLY) is the lower-risk stock at 0.

53β versus Doximity, Inc. 's 0. 75β — meaning DOCS is approximately 41% more volatile than LLY relative to the S&P 500. On balance sheet safety, Doximity, Inc. (DOCS) carries a lower debt/equity ratio of 1% versus 160% for Eli Lilly and Company — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Eli Lilly and Company (LLY) is pulling ahead at 44.

7% versus 13. 1% for Doximity, Inc. (DOCS). On earnings-per-share growth, the picture is similar: Eli Lilly and Company grew EPS 96. 0% year-over-year, compared to -11. 7% for Doximity, Inc.. Over a 3-year CAGR, LLY leads at 31. 7% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Eli Lilly and Company (LLY) is the more profitable company, earning 31.

7% net margin versus 30. 4% for Doximity, Inc. — meaning it keeps 31. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: LLY leads at 45. 6% versus 33. 3% for DOCS. At the gross margin level — before operating expenses — DOCS leads at 89. 1%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Doximity, Inc. (DOCS) is the more undervalued stock at a PEG of 0. 27x versus Eli Lilly and Company's 1. 07x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Doximity, Inc. (DOCS) trades at 14. 0x forward P/E versus 30. 9x for Eli Lilly and Company — 17. 0x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for DOCS: 47. 1% to $29. 47.

In this comparison, LLY (0.

5% yield) pays a dividend. DOCS does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Eli Lilly and Company (LLY) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

53), 0. 5% yield, +1485% 10Y return). Both have compounded well over 10 years (LLY: +1485%, DOCS: -62. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: DOCS is a small-cap quality compounder stock; LLY is a mega-cap high-growth stock. LLY pays a dividend while DOCS does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.